The Most Important Advances in Precision Medicine Being Presented at ASCO 2018Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr David Spigel reviews 3 of the most important, practice-changing topics at ASCO 2018: new therapies targeting RET in a number of tumor types, a prognostic biomarker assay to predict whether patients with breast cancer will need adjuvant hormonal therapy or chemotherapy, and the minimum level of PD-L1 positivity required to predict outcomes with immunotherapy in lung cancer.
Dr Mary Fidler of Rush University Medical Center, Chicago, IL, and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, describe their practical experiences with TRK inhibitors in patients with lung cancer and colorectal cancer.
Ken Schaecher, MD, presents his own personal opinion on the multiple barriers to affordable high quality care for cancer patients. Supported through funding from Incyte